Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.

which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and differentiate its products to stay ahead of the competition.

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Competitors are developing their own innovative treatments, which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Macupatide is under clinical development by Eli Lilly and Co and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 64% phase transition ...